Press Release: BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update

Dow Jones
Nov 03
   -- Delivered the first global data for any PD-(L)1xVEGF bispecific 
      immunomodulator candidate in combination with an investigational 
      antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart 
      drozuntecan 
 
   -- Advanced the first global Phase 3 clinical trial to evaluate pumitamig in 
      combination with Gilead's TROP2-directed antibody-drug conjugate 
      sacituzumab govitecan in triple-negative breast cancer, pending 
      regulatory approval 
   -- Presented data demonstrating gotistobart nearly doubled median overall 
      survival versus chemotherapy in previously treated squamous non-small 
      cell lung cancer 
   -- Launched variant-adapted COVID-19 vaccine for the 2026/2027 vaccination 
      season in multiple regions worldwide 
   -- Third quarter 2026 revenues of EUR1,289.2 million1, adjusted2 R&D 
      expenses of EUR578.5 million (IFRS R&D expenses of EUR748.1 million), and 
      adjusted SG&A3 expenses of EUR178.5 million 
   -- Raised full-year 2026 revenue guidance midpoint and updated range to 
      EUR1.7--1.9 billion, and maintained strong financial position with cash, 
      cash equivalents and security investments of EUR16.2 billion4 

Conference call and webcast scheduled for November 3, 2026, at 8:00 a.m. EST (2:00 p.m. CET)

MAINZ, Germany, November 3, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today reported financial results for the three and nine months ended September 30, 2026 and provided an update on its corporate progress.

"As 2026 draws to a close, the achievement of numerous important milestones throughout the year demonstrates our commitment to advancing our oncology pipeline, and our combination therapy strategy continues to gain momentum, underscored by the announced first global Phase 3 trial of pumitamig in combination with an antibody-drug conjugate," said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. "With a growing pipeline, key registrational trials, strategic partnerships, and financial strength, BioNTech is well positioned for its next phase of growth as we advance toward becoming a diversified, multi-product company by 2030."

Financial Review for Third Quarter and Year-to-Date 2026

 
                       Third Quarter 2026        Third Quarter 2025 
                  -----------------------------  ----------------------------- 
in millions EUR, 
except per share                   Adjusted                       Adjusted 
data              IFRS Results    Results(2)     IFRS Results    Results(2) 
                  ------------  ---------------  ------------  --------------- 
Revenues               1,289.2          1,289.2       1,518.9          1,518.9 
                  ------------  ---------------  ------------  --------------- 
Net profit / 
 (loss)                  184.5            440.9        (28.7)            752.5 
                  ------------  ---------------  ------------  --------------- 
Diluted profit / 
 (loss) per 
 share                    0.73             1.76        (0.12)             3.11 
                  ------------  ---------------  ------------  --------------- 
Weighted average 
 number of 
 shares 
 outstanding (in 
 millions)(5)              251              251           241              242 
                  ------------  ---------------  ------------  --------------- 
 
 
                        Year-to-date 2026        Year-to-date 2025 
                  -----------------------------  ----------------------------- 
in millions EUR, 
except per share                   Adjusted                       Adjusted 
data              IFRS Results    Results(2)     IFRS Results    Results(2) 
                  ------------  ---------------  ------------  --------------- 
Revenues               1,512.9          1,512.9       1,962.5          1,962.5 
                  ------------  ---------------  ------------  --------------- 
Net loss             (1,168.2)          (615.9)       (831.1)           (27.1) 
                  ------------  ---------------  ------------  --------------- 
Diluted loss per 
 share                  (4.63)           (2.44)        (3.45)           (0.11) 
                  ------------  ---------------  ------------  --------------- 
Weighted average 
 number of 
 shares 
 outstanding (in 
 millions)(5)              252              252           241              241 
                  ------------  ---------------  ------------  --------------- 
 

The figures below compare the third quarter of 2026 and the year-to-date period ended September 30, 2026, to the corresponding prior year periods, except where noted.

Revenues were EUR1,289.2 million for the third quarter of 2026, compared to EUR1,518.9 million. Year-to-date revenues were EUR1,512.9 million, compared to EUR1,962.5 million. The decreases were primarily driven by expected lower market demand for BioNTech's COVID-19 vaccines.

Research and development ("R&D") expenses were EUR748.1 million for the third quarter of 2026, compared to EUR564.8 million. Year-to-date R&D expenses were EUR1,856.1 million, compared to EUR1,599.5 million. R&D expenses were mainly driven by higher expenses for the development of BioNTech's late-stage immuno-oncology ("IO") and antibody-drug conjugate ("ADC") programs and impairment expenses related to intangible assets which are outside of BioNTech's strategic focus.

Adjusted R&D expenses were EUR578.5 million for the third quarter of 2026, compared to EUR479.4 million. Year-to-date adjusted R&D expenses were EUR1,582.7 million, compared to EUR1,514.1 million. Adjusted R&D expenses for both the third quarter and year-to-date period in 2026 exclude impairment expenses related to intangible assets which are outside of BioNTech's strategic focus.

Sales, general and administrative ("SG&A") expenses were EUR178.5 million for the third quarter of 2026, compared to EUR148.5 million. Year-to-date SG&A expenses were EUR527.1 million, compared to EUR406.5 million. The increases were mainly driven by the ongoing pre--launch activities and commercial build-up, expenses associated with BioNTech's global initiative on scaling processes and ERP infrastructure to strengthen operational execution and the inclusion of operations from CureVac. This was partly offset by cost reductions resulting from the execution of initiatives related to BioNTech's pipeline prioritization.

Other operating result was negative EUR134.3 million for the third quarter of 2026, compared to negative EUR704.2 million. Year-to-date other operating result was negative EUR358.6 million, compared to negative EUR730.1 million. The quarterly and year-to-date results were primarily driven by impairment losses and employee related restructuring costs derived from BioNTech's pipeline prioritization execution.

Adjusted other operating result was negative EUR58.9 million for the third quarter of 2026, compared to negative EUR8.4 million. Year-to-date adjusted other operating result was negative EUR91.1 million, compared to negative EUR11.5 million. Adjusted other operating result for the third quarter of 2026 excludes impairment losses and employee-related costs related to BioNTech's pipeline prioritization execution as well as settlement expenses, while the comparable prior year result excludes employee-related costs and settlement expenses. Year-to-date periods in 2026 and 2025 exclude impairment losses, employee-related costs and settlement expenses, while 2025 also excludes a bargain purchase.

Net profit was EUR184.5 million for the third quarter of 2026, compared to a net loss of EUR28.7 million. Year-to-date net loss was EUR1,168.2 million, compared to a net loss of EUR831.1 million.

Adjusted net profit was EUR440.9 million for the third quarter of 2026, compared to an adjusted net profit of EUR752.5 million. Year-to-date adjusted net loss was EUR615.9 million, compared to an adjusted net loss of EUR27.1 million.

Diluted profit per share was EUR0.73 for the third quarter of 2026, compared to a diluted loss per share of EUR0.12. Year-to-date diluted loss per share was EUR4.63, compared to a diluted loss per share of EUR3.45.

Adjusted diluted profit per share was EUR1.76 for the third quarter of 2026, compared to adjusted diluted profit per share of EUR3.11. Year-to-date adjusted diluted loss per share was EUR2.44, compared to an adjusted diluted loss per share of EUR0.11.

Cash, cash equivalents and security investments as of September 30, 2026 were EUR16,163.8 million, comprising EUR10,200.8 million in cash and cash equivalents, EUR4,390.2 million in current security investments disclosed as financial assets and EUR1,572.8 million in non-current security investments disclosed as financial assets.

Shares outstanding as of September 30, 2026 were 247,928,180, excluding 11,099,307 shares held in treasury.

In May 2026, BioNTech entered into a share repurchase program, pursuant to which the Company may purchase American Depositary Shares ("ADSs"), each representing one ordinary share of the Company, in the amount of up to $1.0 billion until and including May 6, 2027. Since the inception of the program through September 30, 2026, 5,037,452 ADSs were repurchased at an average price of $91.98 (EUR80.10), for total consideration of $463.3 million (EUR403.5 million).

"Our performance in the third quarter allowed us to narrow our full-year 2026 revenue guidance to the upper end of the previous guidance range," said Ramón Zapata, Chief Financial Officer at BioNTech. "Fueled by our financial strength, we continue to focus our investments on our prioritized late-stage oncology programs. While we further enhance our operational efficiency and cost discipline, we return capital to shareholders through our share repurchase program. Together, these steps are aimed at creating sustainable long-term value."

Updated 2026 Financial Year Guidance(6) :

 
                            FY 2026 non-IFRS Guidance 
                            ----------------------------------------------- 
                                   Current                  Prior 
                                 Nov. 3, 2026            Aug. 4, 2026 
                            ---------------------  ------------------------ 
                            EUR1,700 -- EUR1,900     EUR1,600 -- EUR1,900 
Revenues                     million                        million 
                            ---------------------  ------------------------ 
                                                     EUR2,000 -- EUR2,300 
Adjusted R&D expenses       Unchanged                       million 
                            ---------------------  ------------------------ 
Adjusted SG&A expenses(3)   Unchanged              EUR700 -- EUR800 million 
                            ---------------------  ------------------------ 
 

BioNTech is raising the midpoint of its previously provided full-year 2026 revenue guidance. The updated guidance follows the Company's revenue performance in the third quarter. The guidance for adjusted R&D expenses as well as adjusted SG&A expenses remains unchanged.

BioNTech exercised an option in the existing collaboration agreement with Roche/Genentech where, under the terms of the agreement, future R&D costs related to the program will be generally assigned to Roche/Genentech effective January 1, 2027, while BioNTech will be eligible to receive royalties in case of successful development and commercialization.

The updated terms pursuant to the exercised option under the existing agreement align with BioNTech's broader capital allocation framework and will not affect the ongoing pancreatic ductal adenocarcinoma ("PDAC") trial, which will continue as planned.

While this decision follows the regular assessment of the financial structure of existing collaborations, BioNTech's broader commitment to mRNA and its potential in oncology remains unchanged. Its conviction in mRNA is anchored by over a decade of translational and clinical research, as well as deep experience in the field. BioNTech continues to advance mRNA cancer immunotherapies and invest in them as a key pillar of its oncology strategy, including novel combination approaches intended to maximize the potential of its diversified oncology pipeline.

The full interim unaudited condensed consolidated financial statements can be found in BioNTech's Report on Form 6-K for the period ended September 30, 2026, filed today with the United States Securities and Exchange Commission ("SEC") and available at www.sec.gov.

Endnotes

(1) All numbers in this press release have been rounded.

(2) In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of the Company's business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found at the end of this press release and in BioNTech's Report on Form 6-K for the period ended September 30, 2026, filed on November 3, 2026, which is available at www.sec.gov. The weighted average number of shares outstanding is excluded from that reconciliation. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside the Company's financial statements prepared in accordance with IFRS Accounting Standards. Unless otherwise indicated, Adjusted Results are identical to IFRS Results.

(3) Sales, general and administrative expenses ("SG&A") include sales and marketing expenses as well as general and administrative expenses. Adjusted SG&A expenses include adjusted sales and marketing expenses as well as adjusted general and administrative expenses.

(4) As of September 30, 2026.

(5) Only basic EPS are calculated in loss making periods. Diluted EPS include outstanding instruments from BioNTech's share-based payment programs. The weighted average number of shares outstanding is determined as described in BioNTech's Annual Report on Form 20-F as of and for the year ended December 31, 2025, as amended and is not adjusted by non-IFRS measures.

(6) Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions ("M&A") transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech's Report on Form 6-K for the period ended September 30, 2026, filed on November 3, 2026, which is available at www.sec.gov.

(7) An overview of abbreviations of target structures and indications is compiled in a directory at the end of this press release.

Variant-adapted COVID-19 Vaccine

In the third quarter of 2026, BioNTech and Pfizer executed the commercial launch of their variant-adapted COVID-19 vaccine for the 2026/2027 vaccination season.

   -- In July 2026, BioNTech and Pfizer's monovalent XFG-adapted COVID-19 
      vaccine was approved by the European Commission following recommendation 
      for marketing authorization by the European Medicines Agency's ("EMA") 
      Committee for Medicinal Products for Human Use ("CHMP"). The companies 
      began shipments of the vaccine after approval to ensure rapid access of 
      the season's vaccine. 
 
   -- In August 2026, the United States Food and Drug Administration ("FDA") 
      approved the supplemental Biologics License Application ("sBLA") for 
      BioNTech and Pfizer's monovalent XFG-adapted COVID-19 vaccine for use in 
      adults ages 65 years and older, as well as in individuals ages 5 through 
      64 years with at least one underlying condition that puts them at high 
      risk for severe outcomes from COVID-19. The new variant-adapted COVID-19 
      vaccine was shipped immediately following approval and was made available 
      in pharmacies, hospitals, and clinics across the United States. 

Select Oncology Pipeline Updates

Next-Generation Immunomodulators and Combinations

Pumitamig (BNT327/BMS986545) is an investigational bispecific immunomodulator combining PD-L1(7) checkpoint inhibition with VEGF-A neutralization that is being developed in collaboration with Bristol Myers Squibb Company ("BMS").

   -- Pumitamig is currently being evaluated in seven pivotal trials across the 
      ROSETTA clinical development program, with five new global clinical 
      trials initiated in 2026 spanning triple-negative breast cancer ("TNBC"), 
      colorectal cancer ("CRC"), gastric cancer, and non-small cell lung cancer 
      ("NSCLC"), including two clinical trials in patients with unresectable 
      stage III NSCLC, advanced disease and high PD-L1 expression (TPS >=50%), 
      respectively. 
 
   -- A global Phase 2 clinical trial (ROSETTA Lung-107; NCT06841055) is being 
      conducted to evaluate pumitamig in combination with docetaxel as a 
      second-line treatment for patients with NSCLC. In October 2026, data from 
      this trial were presented at the European Society for Medical Oncology 
      ("ESMO") Congress 2026. Pumitamig in combination with docetaxel showed 
      encouraging antitumor activity with a manageable safety profile in 
      patients with metastatic NSCLC post-chemoimmunotherapy. These data extend 
      evidence for pumitamig's NSCLC development program into the second-line 
      setting where there remains high unmet medical need, representing the 
      third global Phase 2 dataset in lung cancer. 
 
   -- Global Phase 2 clinical trials (NCT06449209 and NCT06449222) are being 
      conducted to evaluate pumitamig in combination with chemotherapy in 
      patients with untreated extensive-stage small cell lung cancer 
      ("ES-SCLC") and in patients with small cell lung cancer ("SCLC") that 
      progressed after first- or second-line treatment and as a first- and 
      second-line treatment for patients with locally advanced or metastatic 
      TNBC, respectively. In October 2026, data from a subgroup analysis in 
      patients with brain metastases from these trials were presented at the 
      ESMO Congress 2026. Patients with TNBC or SCLC and brain metastases at 
      baseline benefited clinically from pumitamig plus chemotherapy both 
      systemically and intracranially, supporting pumitamig's potential across 
      difficult-to-treat tumor types and patient populations. 
 
   -- BioNTech entered into a clinical trial collaboration and supply agreement 
      with Gilead Sciences Inc. ("Gilead") to evaluate pumitamig in combination 
      with the TROP2-directed ADC sacituzumab govitecan as first-line treatment 
      for patients with PD-L1 low or negative locally advanced or metastatic 
      TNBC in the ROSETTA Breast-01 trial. Pending regulatory approval, this 
      will be the first global Phase 3 clinical trial (NCT07173751) of 
      pumitamig in combination with an ADC, reflecting the evolving standard of 
      care in 1L TNBC. 
 
   -- Pumitamig is also being evaluated in additional solid tumor indications, 
      including first-line hepatocellular carcinoma ("HCC"), second-line 
      glioblastoma ("GBM"), first-line PDAC and first-line renal cell carcinoma 
      ("RCC") in various Phase 1/2 and Phase 2 trials, both as monotherapy and 
      in combination with standard of care. 

BioNTech has several signal-seeking clinical trials ongoing evaluating pumitamig with the Company's proprietary assets:

   -- A Phase 2 clinical trial (NCT06953089) is being conducted to evaluate 
      elfetabart drozuntecan (BNT324/DB-1311) in combination with pumitamig. In 
      October 2026, data from this trial were presented at the ESMO Congress 
      2026. Elfetabart drozuntecan in combination with pumitamig was well 
      tolerated and encouraging antitumor activity was observed in patients 
      across multiple tumor types. These data support the potential of 
      pumitamig as a backbone in novel treatment combinations, furthering 
      BioNTech's combination strategy across multiple tumor types with high 
      unmet medical need. They also help build the body of evidence for 
      pumitamig in combination with ADCs that will inform potential 
      registrational trials. 
 
   -- A Phase 1/2 clinical trial (NCT06892548) is being conducted to evaluate 
      elfetabart drozuntecan (BNT324/DB-1311) in combination with pumitamig in 
      patients with advanced lung cancers. In September 2026, data from this 
      trial were presented at the IASLC 2026 World Conference on Lung Cancer 
      ("WCLC"). Elfetabart drozuntecan in combination with pumitamig showed 
      encouraging early efficacy and a manageable safety profile in SCLC, 
      across lines of therapy and dose levels. These were the first data in 
      lung cancer for any investigational PD-(L)1xVEGF bispecific 
      immunomodulator combined with an ADC candidate, underscoring BioNTech's 
      leadership in developing novel-novel combination treatment strategies. 

Gotistobart (BNT316/ONC-392) is a tumor microenvironment-selective regulatory T cell depletion candidate that targets CTLA-4 and is being developed in collaboration with OncoC4, Inc. ("OncoC4").

   -- A global Phase 3 clinical trial (PRESERVE-003; NCT05671510) is ongoing to 
      evaluate the efficacy and safety of gotistobart as monotherapy in 
      patients with metastatic squamous NSCLC that progressed on previous 
      platinum-based chemotherapy and PD-(L)1-inhibitor treatment. 
 
          -- In September 2026, updated data from the stage 1 of this trial 
             were presented at WCLC. Data demonstrated that gotistobart nearly 
             doubled median overall survival ("OS") versus chemotherapy in 
             patients with squamous NSCLC who had progressed on PD-(L)1 
             inhibitors. 
   -- Gotistobart continues to show potential as a chemotherapy-free 
      monotherapy in a hard-to-treat lung cancer setting. 
   -- Based on current event accrual projections, the first interim analysis 
      from stage 2 of the Phase 3 clinical trial is expected in 2026. This will 
      be assessed by the Independent Data Monitoring Committee ("IDMC") to 
      recommend whether to unblind the trial or continue to the next 
      pre-planned interim analysis. 

Antibody-Drug Conjugates

Trastuzumab pamirtecan (BNT323/DB-1303) is an ADC candidate targeting HER2 that is being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. ("DualityBio").

   -- Trastuzumab pamirtecan is being evaluated in two Phase 3 clinical trials 
      in HR-positive, HER2-low metastatic breast cancer (NCT06018337) and 
      HER2-expressing endometrial cancer ("EC") (NCT06340568). 
 
   -- The global Phase 3 clinical trial DYNASTY-Breast02 (NCT06018337) to 
      evaluate trastuzumab pamirtecan in patients with HR-positive, HER2-low 
      metastatic breast cancer met its primary endpoint demonstrating a 
      statistically significant, yet modest improvement in progression-free 
      survival ("PFS") compared to investigator's choice of chemotherapy. At 
      this interim analysis for the secondary endpoint of OS, data were not 
      mature. A higher rate of interstitial lung disease ("ILD") was reported 
      in this trial compared to prior trials with trastuzumab pamirtecan, with 
      most cases being Grade 1 and 2. Severe and fatal events were reported in 
      a small proportion of patients (Grade 3 to 5). Otherwise, the overall 
      safety profile was consistent with prior clinical trials and no new 
      safety signals were observed. 
 
   -- The available efficacy and safety data, as of this data cut-off date, 
      suggest that the potential benefit to patients would be limited in the 
      context of the HR+/HER2-low metastatic breast cancer treatment landscape. 
 
   -- BioNTech and DualityBio are currently discussing the totality of clinical 
      data for trastuzumab pamirtecan across endometrial and breast cancer, 
      within the context of the evolving treatment landscape, and areas of 
      unmet medical need, and will determine the next steps. 
 
   -- As part of this, BioNTech and DualityBio are discussing plans for a BLA 
      submission and will update the markets accordingly. 

mRNA Cancer Immunotherapies

Autogene cevumeran (BNT122/RO7198457) is an mRNA cancer immunotherapy candidate for individualized neoantigen-specific immunotherapy ("iNeST") that is being developed in collaboration with Genentech, Inc. ("Genentech"), a member of the Roche Group ("Roche").

   -- Early termination was initiated in a randomized Phase 2 clinical trial 
      (NCT04486378) to evaluate autogene cevumeran as an adjuvant treatment of 
      circulating tumor DNA, or ctDNA, positive, surgically resected Stage II 
      (high risk)/Stage III CRC compared to watchful waiting after surgery and 
      chemotherapy, which is the current standard of care for these high-risk 
      patients. 
 
   -- The Phase 2 clinical trial IMcode003 (NCT05968326) evaluating autogene 
      cevumeran in combination with checkpoint inhibition and chemotherapy in 
      adjuvant PDAC is not affected and continues as planned. In August 2026, 
      the trial completed enrollment. 

BNT113 is an mRNA cancer immunotherapy candidate and based on BioNTech's fully owned, off-the-shelf FixVac platform, encoding the two oncoproteins E6 and E7 that are frequently found in human papillomavirus type 16 positive ("HPV16+") solid tumors.

   -- In October 2026, the first topline results from the AHEAD-MERIT Phase 2/3 
      clinical trial (NCT04534205) were announced. The Phase 3 part of 
      AHEAD-MERIT has dual primary endpoints, PFS and OS, providing 
      complementary measures of clinical benefit. At the analysis for PFS, 
      BNT113 in combination with pembrolizumab did not demonstrate a 
      statistically significant improvement in PFS versus pembrolizumab alone. 
      The IDMC has recommended that the clinical trial continues as planned to 
      evaluate the second primary endpoint of OS to complete the assessment of 
      the potential of this approach to help patients live longer. As 
      immune-mediated anti-tumor effects build and deepen over time, the 
      analysis of the second dual primary endpoint, OS, will be critical to 
      fully assess the potential of this approach. Under the trial's 
      pre-specified statistical design, a statistically significant improvement 
      in OS would establish a positive trial outcome, even if the PFS dual 
      primary endpoint was not met. BioNTech remains blinded to ongoing trial 
      data in accordance with the trial's governance procedures. 

Upcoming Investor and Analyst Events

   -- BioNTech Fourth Quarter and Full Year 2026 Financial Results and 
      Corporate Update: March 2, 2027 

Conference Call and Webcast Information

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, November 3, 2026, at 8:00 a.m. EST (2:00 p.m. CET) to report its financial results and provide a corporate update for the third quarter of 2026.

To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN number will be provided.

The slide presentation and audio of the webcast will be available via this link.

Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page of the Investor section of the Company's website at www.BioNTech.com. A replay of the webcast will be made available shortly after the closing of the call and archived on the Company's website for 30 days following the call.

About BioNTech

BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or clinical trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech's expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational clinical trials, and the registrational potential of any clinical trial BioNTech may initiate; BioNTech's expectations regarding the impact of changes to its manufacturing operations; discussions with regulatory agencies; BioNTech's expectations with respect to intellectual property; the impact of BioNTech's collaboration and licensing agreements; BioNTech's expectations with respect to developments in law, public policy, and international trade; BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech's expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech's current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or annual booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech's other product candidates; the timing of and BioNTech's ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and market its product candidates, if approved; BioNTech's ability to manage its development and related expenses; regulatory and political developments; BioNTech's ability to effectively scale its production capabilities and manufacture its products and product candidates; expected changes to BioNTech's leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Report on Form 6-K for the period ended September 30, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

CONTACTS

Investor Relations

Douglas Maffei, PhD

Investors@biontech.de

Media Relations

Jasmina Alatovic

Media@biontech.de

Abbreviation Overview

 
ADC      Antibody-drug conjugate 
-------  ------------------------------------------------ 
BLA      Biologics license application 
-------  ------------------------------------------------ 
CRC      Colorectal cancer 
-------  ------------------------------------------------ 
ctDNA    Circulating tumor DNA 
-------  ------------------------------------------------ 
CTLA-4   Cytotoxic T-lymphocyte-associated protein 
          4 
-------  ------------------------------------------------ 
EC       Endometrial cancer 
-------  ------------------------------------------------ 
ES-SCLC  Extensive-stage small cell lung cancer 
-------  ------------------------------------------------ 
GBM      Glioblastoma 
-------  ------------------------------------------------ 
HCC      Hepatocellular carcinoma 
-------  ------------------------------------------------ 
HER2     Human epidermal growth factor receptor 
          2 
-------  ------------------------------------------------ 
HPV16+   Human papillomavirus type 16 positive 
-------  ------------------------------------------------ 
HR       Hormone receptor 
-------  ------------------------------------------------ 
IDMC     Independent Data Monitoring Committee 
-------  ------------------------------------------------ 
ILD      Interstitial lung disease 
-------  ------------------------------------------------ 
iNeST    Individualized neoantigen-specific immunotherapy 
-------  ------------------------------------------------ 
IO       Immuno-oncology 
         ------------------------------------------------ 
mRNA     Messenger ribonucleic acid 
-------  ------------------------------------------------ 
NSCLC    Non-small cell lung cancer 
-------  ------------------------------------------------ 
OS       Overall survival 
-------  ------------------------------------------------ 
PDAC     Pancreatic ductal adenocarcinoma 
-------  ------------------------------------------------ 
PD-(L)1  Programmed cell death protein (death-ligand) 
          1 
-------  ------------------------------------------------ 
PFS      Progression-free survival 
-------  ------------------------------------------------ 
RCC      Renal cell carcinoma 
-------  ------------------------------------------------ 
SCLC     Small cell lung cancer 
-------  ------------------------------------------------ 
TPS      Tumor Proportion Score 
-------  ------------------------------------------------ 
TNBC     Triple-negative breast cancer 
-------  ------------------------------------------------ 
TROP2    Trophoblast cell surface antigen 2 
-------  ------------------------------------------------ 
VEGF-A   Vascular endothelial growth factor A 
-------  ------------------------------------------------ 
 

Interim Condensed Consolidated Statements of Profit or Loss

 
                               Three months ended     Nine months ended 
                                  September 30,        September 30, 
                               2026         2025         2026         2025 
(in millions EUR, except 
per share data)             (unaudited)  (unaudited)  (unaudited)  (unaudited) 
                            -----------  -----------  -----------  ----------- 
Revenues                        1,289.2      1,518.9      1,512.9      1,962.5 
                            -----------  -----------  -----------  ----------- 
Cost of sales                   (103.3)      (148.3)      (271.7)      (308.5) 
                            -----------  -----------  -----------  ----------- 
Research and development 
 expenses                       (748.1)      (564.8)    (1,856.1)    (1,599.5) 
                            -----------  -----------  -----------  ----------- 
Sales and marketing 
 expenses                        (43.3)       (27.3)      (111.3)       (60.7) 
                            -----------  -----------  -----------  ----------- 
General and administrative 
 expenses                       (135.2)      (121.2)      (415.8)      (345.8) 
                            -----------  -----------  -----------  ----------- 
Other operating expenses        (163.6)      (729.5)      (443.7)      (884.7) 
                            -----------  -----------  -----------  ----------- 
Other operating income             29.3         25.3         85.1        154.6 
                            -----------  -----------  -----------  ----------- 
Operating profit / (loss)         125.0       (46.9)    (1,500.6)    (1,082.1) 
                            -----------  -----------  -----------  ----------- 
Finance income                    105.3         96.8        323.2        324.8 
                            -----------  -----------  -----------  ----------- 
Finance expenses                  (8.3)       (25.2)       (27.4)       (66.1) 
                            -----------  -----------  -----------  ----------- 
Profit / (Loss) before tax        222.0         24.7    (1,204.8)      (823.4) 
                            -----------  -----------  -----------  ----------- 
Income taxes                     (37.5)       (53.4)         36.6        (7.7) 
                            -----------  -----------  -----------  ----------- 
Net profit / (loss)               184.5       (28.7)    (1,168.2)      (831.1) 
                            -----------  -----------  -----------  ----------- 
Earnings / (Loss) per 
share 
Basic profit / (loss) per 
 share                             0.74       (0.12)       (4.63)       (3.45) 
                            -----------  -----------  -----------  ----------- 
Diluted profit / (loss) 
 per share                         0.73       (0.12)       (4.63)       (3.45) 
                            -----------  -----------  -----------  ----------- 
 

Interim Condensed Consolidated Statements of Financial Position

 
                                               September   December 
                                                   30         31, 
(in millions EUR)                                2026        2025 
Assets                                        (unaudited) 
                                              ----------- 
Non-current assets 
Goodwill                                            376.0      367.9 
                                              -----------  --------- 
Other intangible assets                           1,201.6    1,606.0 
                                              -----------  --------- 
Property, plant and equipment                     1,000.9    1,080.9 
                                              -----------  --------- 
Right-of-use assets                                 159.2      210.2 
                                              -----------  --------- 
Contract assets                                        --        2.0 
                                              -----------  --------- 
Other financial assets                            1,727.3    2,554.2 
                                              -----------  --------- 
Other assets                                         15.0        7.3 
                                              -----------  --------- 
Deferred tax assets                                  20.0       13.5 
                                              -----------  --------- 
Total non-current assets                          4,500.0    5,842.0 
                                              -----------  --------- 
Current assets 
Inventories                                          64.9      110.7 
                                              -----------  --------- 
Trade and other receivables                         666.3      924.2 
                                              -----------  --------- 
Contract assets                                       5.4        8.1 
                                              -----------  --------- 
Other financial assets                            4,457.6    7,201.8 
                                              -----------  --------- 
Other assets                                        145.2      173.8 
                                              -----------  --------- 
Income tax assets                                   124.3       52.6 
                                              -----------  --------- 
Cash and cash equivalents                        10,200.8    7,675.4 
                                              -----------  --------- 
Assets held for sale                                  9.3         -- 
                                              -----------  --------- 
Total current assets                             15,673.8   16,146.6 
                                              -----------  --------- 
Total assets                                     20,173.8   21,988.6 
                                              -----------  --------- 
 
Equity and liabilities 
Equity 
Share capital                                       259.0      259.0 
                                              -----------  --------- 
Capital reserve                                   2,076.5    2,473.3 
                                              -----------  --------- 
Treasury shares                                    (11.1)      (7.7) 
                                              -----------  --------- 
Retained earnings                                16,793.7   17,961.9 
                                              -----------  --------- 
Other reserves                                  (1,406.4)  (1,462.3) 
                                              -----------  --------- 
Total equity                                     17,711.7   19,224.2 
                                              -----------  --------- 
Non-current liabilities 
Lease liabilities, loans and borrowings             255.4      215.2 
                                              -----------  --------- 
Other financial liabilities                         108.9       94.9 
                                              -----------  --------- 
Provisions                                           64.6       35.5 
                                              -----------  --------- 
Contract liabilities                                  0.7       88.0 
                                              -----------  --------- 
Other liabilities                                   117.1      104.2 
                                              -----------  --------- 
Deferred tax liabilities                             82.6       84.3 
                                              -----------  --------- 
Total non-current liabilities                       629.3      622.1 
                                              -----------  --------- 
Current liabilities 
Lease liabilities, loans and borrowings             104.4       52.2 
                                              -----------  --------- 
Trade payables and other payables                   523.1      534.9 
                                              -----------  --------- 
Other financial liabilities                         141.2      351.7 
                                              -----------  --------- 
Income tax liabilities                               13.2       65.6 
                                              -----------  --------- 
Provisions                                          244.2      145.3 
                                              -----------  --------- 
Contract liabilities                                623.6      754.9 
                                              -----------  --------- 
Other liabilities                                   181.1      237.7 
                                              -----------  --------- 
Liabilities related to assets held for sale           2.0         -- 
                                              -----------  --------- 
Total current liabilities                         1,832.8    2,142.3 
                                              -----------  --------- 
Total liabilities                                 2,462.1    2,764.4 
                                              -----------  --------- 
Total equity and liabilities                     20,173.8   21,988.6 
                                              -----------  --------- 
 

Interim Condensed Consolidated Statements of Cash Flows

 
                                  Three months              Nine months 
                                      ended                     ended 
                                  September 30,             September 30, 
                               2026         2025         2026         2025 
(in millions EUR)           (unaudited)  (unaudited)  (unaudited)  (unaudited) 
                            -----------  -----------  -----------  ----------- 
Operating activities 
Net profit / (loss)               184.5       (28.7)    (1,168.2)      (831.1) 
                            -----------  -----------  -----------  ----------- 
Income taxes                       37.5         53.4       (36.6)          7.7 
                            -----------  -----------  -----------  ----------- 
Profit / (Loss) before tax        222.0         24.7    (1,204.8)      (823.4) 
                            -----------  -----------  -----------  ----------- 
Adjustments to reconcile 
profit / (loss) before tax 
to net cash flows: 
  Depreciation, 
   amortization and 
   impairment of property, 
   plant, equipment, 
   intangible assets and 
   right-of-use assets            332.3        124.2        719.7        218.0 
--------------------------  -----------  -----------  -----------  ----------- 
  Share-based payment 
   expenses                        20.0         27.9         63.7         82.1 
--------------------------  -----------  -----------  -----------  ----------- 
  Net foreign exchange 
   differences                    (3.2)       (24.1)         14.3         36.4 
--------------------------  -----------  -----------  -----------  ----------- 
  Gain on disposal of 
   property, plant and 
   equipment                      (0.1)        (1.3)        (1.1)        (1.7) 
--------------------------  -----------  -----------  -----------  ----------- 
  Finance income excluding 
   foreign exchange 
   differences                   (96.3)       (96.8)      (301.9)      (324.8) 
--------------------------  -----------  -----------  -----------  ----------- 
  Finance expense 
   excluding foreign 
   exchange differences             8.3          2.6         27.4         17.1 
--------------------------  -----------  -----------  -----------  ----------- 
  Government and similar 
   grants                        (13.2)       (10.5)       (45.3)       (43.5) 
--------------------------  -----------  -----------  -----------  ----------- 
  Other non-cash income              --           --           --       (15.0) 
--------------------------  -----------  -----------  -----------  ----------- 
Working capital 
adjustments: 
  Decrease / (Increase) in 
   trade and other 
   receivables, contract 
   assets and other 
   assets                       (489.1)        897.1        308.1      1,005.5 
--------------------------  -----------  -----------  -----------  ----------- 
  Decrease in inventories          33.5          5.1         43.7         61.7 
--------------------------  -----------  -----------  -----------  ----------- 
  Decrease in trade 
   payables, other 
   financial liabilities, 
   other liabilities, 
   contract liabilities, 
   refund liabilities and 
   provisions                   (197.6)      (242.5)      (344.8)      (314.9) 
--------------------------  -----------  -----------  -----------  ----------- 
Interest received and 
 realized gains from cash 
 and cash equivalents              78.0         83.5        235.4        275.2 
                            -----------  -----------  -----------  ----------- 
Interest paid and realized 
 losses from cash and cash 
 equivalents                      (2.8)        (2.4)        (8.4)        (8.2) 
                            -----------  -----------  -----------  ----------- 
Income tax paid, net             (33.7)        (9.6)       (91.4)       (36.7) 
                            -----------  -----------  -----------  ----------- 
Share-based payments              (4.2)        (4.2)       (19.2)       (19.3) 
                            -----------  -----------  -----------  ----------- 
Government and similar 
 grants received                   16.3          7.0         64.3         38.0 
                            -----------  -----------  -----------  ----------- 
Net cash flows from / 
 (used in) operating 
 activities                     (129.8)        780.7      (540.3)        146.5 
                            -----------  -----------  -----------  ----------- 
Investing activities 
Purchase of property, 
 plant and equipment             (33.6)       (35.9)      (145.0)      (111.9) 
                            -----------  -----------  -----------  ----------- 
Proceeds from sale of 
 property, plant and 
 equipment                          1.5          2.9          6.5          3.9 
                            -----------  -----------  -----------  ----------- 
Purchase of intangible 
 assets                          (14.9)        (2.7)       (37.8)      (575.0) 
                            -----------  -----------  -----------  ----------- 
Acquisition of 
 subsidiaries and 
 businesses, net of cash 
 acquired                        (31.8)           --       (31.8)       (78.5) 
                            -----------  -----------  -----------  ----------- 
Investment in other 
 financial assets             (1,504.9)    (2,869.0)    (5,111.0)    (7,046.7) 
                            -----------  -----------  -----------  ----------- 
Proceeds from maturity of 
 other financial assets         2,391.4      1,979.4      8,677.3      8,065.3 
                            -----------  -----------  -----------  ----------- 
Net cash flows from / 
 (used in) investing 
 activities                       807.7      (925.3)      3,358.2        257.1 
                            -----------  -----------  -----------  ----------- 
Financing activities 
Proceeds from loans and 
 borrowings                        52.9           --        129.1           -- 
                            -----------  -----------  -----------  ----------- 
Repayment of loans and 
 borrowings                          --        (1.2)        (5.9)        (9.4) 
                            -----------  -----------  -----------  ----------- 
Payments related to lease 
 liabilities                     (11.2)       (10.3)       (34.4)       (29.2) 
                            -----------  -----------  -----------  ----------- 
Share repurchase program        (274.3)           --      (403.5)           -- 
                            -----------  -----------  -----------  ----------- 
Net cash flows used in 
 financing activities           (232.6)       (11.5)      (314.7)       (38.6) 
                            -----------  -----------  -----------  ----------- 
Net increase / (decrease) 
 in cash and cash 
 equivalents                      445.3      (156.1)      2,503.2        365.0 
                            -----------  -----------  -----------  ----------- 
Change in cash and cash 
 equivalents resulting 
 from exchange rate 
 differences                        2.0       (21.5)        (4.7)       (28.4) 
                            -----------  -----------  -----------  ----------- 
Change in cash and cash 
 equivalents resulting 
 from other valuation 
 effects                           12.5          1.0         26.9        (5.6) 
                            -----------  -----------  -----------  ----------- 
Cash and cash equivalents 
 at the beginning of the 
 period                         9,741.0     10,269.5      7,675.4      9,761.9 
                            -----------  -----------  -----------  ----------- 
Cash and cash equivalents 
 as of September 30            10,200.8     10,092.9     10,200.8     10,092.9 
                            -----------  -----------  -----------  ----------- 
 

Certain prior period lines were aggregated to conform to current period presentation and to improve readability.

Non-IFRS Reconciliation

 
Non-IFRS Reconciliation for the three months ended September 
 30, 2026 
                                            non-IFRS adjustments (unaudited) 
                                 ------------------------------------------------------ 
                       IFRS                                                               Adjusted 
                      Results                                                              Results 
                                 -----------  ----------  ----------------  ----------- 
                                                                            Income from 
                                                                              bargain 
                                                                             purchase 
                                                                            and income 
                                                                                and 
                                                                             expenses 
                                  Expenses                                     from 
(in millions EUR,                and income   Impairment  Employee-related  divestiture 
 except per share                from legal      and       expenses from      related 
 data)              (unaudited)  proceedings   reversal    restructuring       items     (unaudited) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Cost of sales           (103.3)           --        11.4                --           --       (91.9) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Research and 
 development 
 expenses               (748.1)           --       169.6                --           --      (578.5) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Other operating 
 expenses               (163.6)         13.5        42.2              19.7           --       (88.2) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Operating profit          125.0         13.5       223.2              19.7           --        381.4 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Profit before tax         222.0         13.5       223.2              19.7           --        478.4 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Net profit(1)             184.5         13.5       223.2              19.7           --        440.9 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Earnings per share 
Basic profit per 
 share                     0.74                                                                 1.76 
                    -----------                                                          ----------- 
Diluted profit per 
 share                     0.73                                                                 1.76 
                    -----------                                                          ----------- 
 

(1) Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

 
Non-IFRS Reconciliation for the three months ended September 
 30, 2025 
                                            non-IFRS adjustments (unaudited) 
                                 ------------------------------------------------------ 
                       IFRS                                                               Adjusted 
                      Results                                                              Results 
                                 -----------  ----------  ----------------  ----------- 
                                                                            Income from 
                                                                              bargain 
                                                                             purchase 
                                                                            and income 
                                                                                and 
                                                                             expenses 
                                  Expenses                                     from 
(in millions EUR,                and income   Impairment  Employee-related  divestiture 
except per share                 from legal      and       expenses from      related 
data)               (unaudited)  proceedings   reversal    restructuring       items     (unaudited) 
                                 -----------  ----------  ----------------  ----------- 
Research and 
 development 
 expenses               (564.8)           --        85.4                --           --      (479.4) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Other operating 
 expenses               (729.5)        678.5          --              17.3           --       (33.7) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Operating profit / 
 (loss)                  (46.9)        678.5        85.4              17.3           --        734.3 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Profit before tax          24.7        678.5        85.4              17.3           --        805.9 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Net profit / 
 (loss)                  (28.7)        678.5        85.4              17.3           --        752.5 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Earnings / (Loss) 
per share 
Basic profit / 
 (loss) per share        (0.12)                                                                 3.12 
                    -----------                                                          ----------- 
Diluted profit / 
 (loss) per share        (0.12)                                                                 3.11 
                    -----------                                                          ----------- 
 

(1) Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

 
Non-IFRS Reconciliation for the nine months ended September 
 30, 2026 
                                            non-IFRS adjustments (unaudited) 
                                 ------------------------------------------------------ 
(in millions EUR, 
except per share       IFRS                                                               Adjusted 
data)                 Results                                                              Results 
                                                                            Income from 
                                                                              bargain 
                                                                             purchase 
                                                                            and income 
                                                                                and 
                                                                             expenses 
                                  Expenses                                     from 
                                 and income   Impairment  Employee-related  divestiture 
                                 from legal      and       expenses from      related 
                    (unaudited)  proceedings   reversal    restructuring       items     (unaudited) 
Cost of sales           (271.7)           --        11.4                --           --      (260.3) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Research and 
 development 
 expenses             (1,856.1)           --       273.4                --           --    (1,582.7) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Other operating 
 expenses               (443.7)         13.5       129.2             124.8           --      (176.2) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Operating loss        (1,500.6)         13.5       414.0             124.8           --      (948.3) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Loss before tax       (1,204.8)         13.5       414.0             124.8           --      (652.5) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Net loss(1)           (1,168.2)         13.5       414.0             124.8           --      (615.9) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Loss per share 
Basic and diluted 
 loss per share          (4.63)                                                               (2.44) 
                    -----------                                                          ----------- 
 

(1) Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

 
Non-IFRS Reconciliation for the nine months ended September 
 30, 2025 
                                            non-IFRS adjustments (unaudited) 
                                 ------------------------------------------------------ 
(in millions EUR, 
except per share       IFRS                                                               Adjusted 
data)                 Results                                                              Results 
                                                                            Income from 
                                                                              bargain 
                                                                             purchase 
                                                                            and income 
                                                                                and 
                                                                             expenses 
                                  Expenses                                     from 
                                 and income   Impairment  Employee-related  divestiture 
                                 from legal      and       expenses from      related 
                    (unaudited)  proceedings   reversal    restructuring       items     (unaudited) 
Research and 
 development 
 expenses             (1,599.5)           --        85.4                --           --    (1,514.1) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Other operating 
 expenses               (884.7)        678.5        10.0              45.1           --      (151.1) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Other operating 
 income                   154.6           --          --                --       (15.0)        139.6 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Operating loss        (1,082.1)        678.5        95.4              45.1       (15.0)      (278.1) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Loss before tax         (823.4)        678.5        95.4              45.1       (15.0)       (19.4) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Net loss(1)             (831.1)        678.5        95.4              45.1       (15.0)       (27.1) 
                    -----------  -----------  ----------  ----------------  -----------  ----------- 
Loss per share 
Basic and diluted 
 loss per share          (3.45)                                                               (0.11) 
                    -----------                                                          ----------- 
 

(1) Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10